David Young - 01 Nov 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
01 Nov 2021
Transactions value $
$0
Form type
4
Filing time
04 Apr 2022, 17:45:04 UTC
Previous filing
06 Jan 2022
Next filing
06 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +4,286 +18.81% $0 27,066 01 Nov 2021 Common Stock 4,286 $0 Direct F1
transaction PCSA Restricted Stock Units Award $0 +10,715 +39.59% $0 37,781 31 Mar 2022 Common Stock 10,715 $0 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.